Literature DB >> 2250315

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma.

S M Luger1, J M Kirkwood, M S Ernstoff, D R Vlock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2250315     DOI： 10.1093/jnci/82.24.1934

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

Review 1.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Immunotherapy with monoclonal antibodies in metastatic melanoma.

Authors:  T A Steffens; D F Bajorin; A N Houghton
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 3.  Gender aspects of treatment and drug related toxicity in medical oncology.

Authors:  Christine Marosi
Journal:  Wien Med Wochenschr       Date:  2006-10

Review 4.  Current treatment options for malignant melanoma.

Authors:  G L Cohen; C I Falkson
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

5.  Neck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin protocol are useful for oral mucosal melanoma.

Authors:  Xi Yang; Guo-Xin Ren; Chen-Ping Zhang; Guo-Yu Zhou; Yong-Jie Hu; Wen-Jun Yang; Wei Guo; Jiang Li; Lai-Ping Zhong
Journal:  BMC Cancer       Date:  2010-11-11       Impact factor: 4.430

6.  Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.

Authors:  N H Mulder; W T van der Graaf; P H Willemse; H S Koops; E G de Vries; D T Sleijfer
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.